CyPath® Lung Clinical Study Validates Noninvasive Lung Cancer Treatment Decisions

summarizeSummary

bioAffinity Technologies announced a new clinical case study demonstrating CyPath® Lung's effectiveness in guiding noninvasive treatment decisions for lung cancer, helping a patient avoid an unnecessary biopsy.

check_boxKey Events

• New Clinical Case Study Released

  bioAffinity Technologies announced a new clinical case study for its CyPath® Lung noninvasive diagnostic test, demonstrating its utility in clinical practice.

• CyPath® Lung Guides Treatment Decision

  The study showed CyPath® Lung helped a 79-year-old patient with a suspicious lung nodule avoid an invasive biopsy, supporting a conservative surveillance strategy.

• Decision Validated by Follow-up Scan

  A subsequent CT scan confirmed the resolution of the suspicious finding, validating the initial decision made with CyPath® Lung's negative result.

• Reduces Diagnostic Burden

  The case study highlights the test's ability to provide objective data, reduce unnecessary invasive procedures, and offer reassurance for high-risk patients.

auto_awesomeAnalysis

This 8-K details a new clinical case study for bioAffinity Technologies' CyPath® Lung diagnostic test, demonstrating its real-world utility in guiding treatment decisions for high-risk lung cancer patients. The case study highlights how a negative CyPath® Lung result, combined with imaging, allowed an elderly patient to avoid an invasive biopsy, with subsequent scans validating the decision. This provides further clinical validation for the company's key product, reinforcing its value proposition in reducing diagnostic burden and improving patient care. For a micro-cap company, such positive clinical evidence is crucial for market adoption and investor confidence.